Literature DB >> 28314326

Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting.

Kiyotaka Yoh1, Yasushi Goto2, Yoichi Naito3, Kazuma Kishi4, Kiyoshi Mori5, Katsuyuki Hotta6, Yukio Hosomi7, Kazuhiko Yamada8, Chiharu Tanai9, Yoshio Tomizawa10, Akira Inoue11, Yoshinori Hasegawa12, Makoto Nishio13, Yasuo Ohashi14, Hideo Kunitoh15.   

Abstract

BACKGROUND: The purpose of this study was to explore the role of maintenance therapy for patients with advanced non-small cell lung cancer (NSCLC) in a real-world setting. PATIENTS AND METHODS: This was a prospective observational cohort multicenter study. Eligible patients were observed from initiation of first-line platinum-based chemotherapy until final follow-up.
RESULTS: Between 2010 and 2011, a total of 864 patients were enrolled in this study. The primary study population was 396 patients who had progressive disease during observation after first-line chemotherapy without maintenance. Of these, 113 patients (29%) did not receive second-line therapy. In contrast, only 18% of patients who had progressive disease during maintenance therapy missed second-line therapy. Overall survival of patients without maintenance who received second-line therapy was similar to that of those who received maintenance, but no second-line therapy.
CONCLUSION: Maintenance therapy for patients with advanced NSCLC might be an appropriate strategy to maximize the chance of receiving more active therapy. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Non-small cell lung cancer; maintenance therapy; platinum-based chemotherapy; second-line therapy

Mesh:

Substances:

Year:  2017        PMID: 28314326     DOI: 10.21873/anticanres.11478

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  The influence of pemetrexed-based continuous maintenance therapy on survival of locally advanced and metastatic lung adenocarcinoma.

Authors:  Yu Huang; Ying Wang; Dandan Hu; Lingjuan Chen; Ruiguang Zhang; Shishi Cheng; Gang Wu; Xiaorong Dong
Journal:  Ann Transl Med       Date:  2019-10

2.  Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis.

Authors:  Seung Sook Paik; In Kyoung Hwang; Myung Jae Park; Seung Hyeun Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2018-03-07

3.  Ang-2 promotes lung cancer metastasis by increasing epithelial-mesenchymal transition.

Authors:  Zhizhen Dong; Jianrong Chen; Xuli Yang; Wenjie Zheng; Li Wang; Miao Fang; Mengna Wu; Min Yao; Dengfu Yao
Journal:  Oncotarget       Date:  2018-01-09

4.  Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.

Authors:  Edward B Garon; Giorgio Vittorio Scagliotti; Oliver Gautschi; Martin Reck; Michael Thomas; Lara Iglesias Docampo; Haralabos Kalofonos; Joo-Hang Kim; Steven Gans; Odd Terje Brustugun; Sergey V Orlov; Gebra Cuyun Carter; Annamaria H Zimmermann; Ana B Oton; Ekaterine Alexandris; Pablo Lee; Katharina Wolff; Victoria Jennifer Stefaniak; Mark A Socinski; Maurice Pérol
Journal:  ESMO Open       Date:  2020-01

5.  Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study.

Authors:  Xiangwei Xu; Ruya Li; Peizhen Zhu; Penghai Zhang; Jun Chen; Yongsheng Lin; Yinqiao Chen
Journal:  World J Surg Oncol       Date:  2021-08-06       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.